Back to Journals » OncoTargets and Therapy » Volume 6

Review

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib

      

Authors Shaw HM, Hall M

Received 11 December 2012

Accepted for publication 15 April 2013

Published 3 September 2013 Volume 2013:6 Pages 1197—1206

DOI https://doi.org/10.2147/OTT.S30748

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 


Heather M Shaw, Marcia Hall

Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, United Kingdom

Abstract: Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose) polymerase inhibitors and reviews the recent literature pertaining to olaparib in ovarian cancer.

Keywords: anticancer, polymerase inhibitor

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]